As­traZeneca, Dai­ichi Sanky­o's ADC En­her­tu blows away Roche's Kad­cy­la in sec­ond-line ad­vanced breast can­cer

As­traZeneca and Japan­ese drug­mak­er Dai­ichi Sankyo think they’ve struck gold with their next-gen ADC drug En­her­tu, which has shown some strik­ing da­ta in late-stage breast …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER